Contact Us   Having technical issues or questions regarding this product?
Please Contact Us.
BEI Resources currently limits the total number of "Made to Order" items which can be ordered by a registrant to 10 "Made to Order" items per 6 month period. Please check the Availability Status on the items you are ordering and limit orders appropriately.
NR-46417  Staphylococcus aureus, AIS 2006045
(Bacteria)
Price: All BEI Resources products are provided
at no cost to registered researchers.
Organism: Staphylococcus aureus
Designations: AIS 2006045
Biosafety Level: 2
Availability Status: In Stock
Store at: -60°C or colder
Contributor: J Patel
Comments:
Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.

Staphylococcus aureus (S. aureus), strain AIS 2006045 (also referred to as VRSA-7, VRS7) was isolated in 2006 in Michigan, USA from a triceps wound of a 43-year-old female with necrotizing fasciitis of the right upper limb who had been recently treated with a five-week course of vancomycin.

S. aureus, strain AIS 2006045 is a vancomycin-resistant S. aureus (VRSA) strain and is reported to be resistant to a number of other antimicrobial agents. S. aureus, strain AIS 2006045 was deposited as positive for mec (subtype II) and vanA; negative for vanB, vanC1, vanC2, vanD, vanE, PVL and arginine catabolic mobile element (ACME); pulsed-field type USA100; spa repeats TJMBMDMGMK; Ridom spa type t002. S. aureus, strain AIS 2006045 is a USA100 isolate. USA100 isolates have the same MLST profile (ST 5) and SCCmec (subtype II) and are usually resistant to β-lactams, erythromycin and spectinomycin as well as being multiresistant to other commonly used therapeutic agents. USA100 is the most prevalent U.S health care-associated pulsed-field type and is endemic in many U.S. hospitals. S. aureus, strain AIS 2006045 is partially dependent on vancomycin for growth due to a mutation in D-alanyl:D-alanine ligase (Ddl), an enzyme involved in biosynthesis of peptidoglycans. The presence of the vanA operon compensates for the Ddl mutation by providing alternative peptidoglycans for cell wall synthesis; however, some have found that this change in the type of peptidoglycans produced renders it susceptible to oxacillin. The complete genome sequence of S. aureus, strain AIS 2006045 is available (GenBank: AHBQ00000000).

Each vial contains approximately 0.5 mL of bacterial culture in Brain Heart Infusion broth supplemented with 6 µg/mL vancomycin and 10% glycerol.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.
Citations: Acknowledgment for publications should read "The following reagent was provided by the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) for distribution by BEI Resources, NIAID, NIH: Staphylococcus aureus, Strain AIS 2006045, NR-46417."
Additional Information: NARSA VRS7
PERMITS
For a list of permits that may be required for shipping this product and to set the permit information preferences; please select a country from the drop down below.

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.

Return to Top


Notices and Disclaimers

BEI Resources products are intended for laboratory research purposes only. They are not intended for use in humans.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this site, BEI Resources makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. BEI Resources does not warrant that such information has been confirmed to be accurate.


Back to My Search